Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in

Status Not yet recruiting

Clinical Trial Summary

Aim of the research is to assess frequency of MAFLD among patients with acute coronary syndromes (ACS).

Clinical Trial Description

Hepatic manifestation of metabolic syndrome (MS) is known as Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). MAFLD could be complicated by serious events as steatohepatitis, cirrhosis and malignant liver. The characteristics histological findings in those patients are macrovesicular steatosis. The prevalence of MAFLD has doubled over the last 20 years. Globally, based on many reported studies, it's well-known that in 25-28% of deaths in patients with Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) , coronary artery disease (CAD) is accused to be the leading cause. Patients with MAFLD are known to have more complex coronary artery disease in angiography. But the effect on clinical outcome and mortality is not known. Furthermore, the impact of MAFLD on acute coronary syndrome (ACS) is not clear. Moreover, in patients with metabolic syndrome the presence of MAFLD would be associated with severe form of CAD as noticed by angiography where there was increased in number of affected vessels and multivariate regression analysis found that MAFLD as the only independent factor affecting coronary score. The SYNTAX score was prospectively developed for the SYNTAX trial to grade the anatomical complexity of coronary lesions in patients with lt main coronary arterty (LM) or three-vessel disease . It was found to be an independent predictor of long-term major adverse cardiac and cerebrovascular events (MACCE) and of death. While the available data clearly support a role of MAFLD in initiating and progression of CAD in non-diabetic patients is still to be searched. MAFLD might play a part in the pathogenesis of CAD through the overexpression and systemic release of several inﬂammatory, hemostatic and oxidative-stress mediators or via contributing to whole-body insulin resistance and atherogenic dyslipidemia. Based on the lack of studies that discussed the effect of MAFLD on patients with ACS ,we designed this study trying to asses the effect of MAFLD on the severity of ACS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06456970
Study type	Observational
Source	Assiut University
Contact	Taiseer Mohamed Kamal El Deen, resident
Phone	01080718330
Email	totym036@gmail.com
Status	Not yet recruiting
Phase
Start date	July 1, 2024
Completion date	July 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT06051669` - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Completed	`NCT02565446` - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram	N/A
Not yet recruiting	`NCT01694342` - Telomere Parameters in Patients With Nonalcoholic Fatty Liver	N/A
Completed	`NCT01464801` - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease	N/A
Completed	`NCT01992809` - Omega 3 Supplementation in Fatty Liver	Phase 3
Completed	`NCT00063635` - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)	Phase 3
Completed	`NCT00244569` - Development of a Breath Test for Monitoring Patients With Liver Disease	Phase 3
Recruiting	`NCT03972319` - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study	Early Phase 1
Completed	`NCT03141008` - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT05125757` - Lifestyle Modification in Psoriatic Patients With Fatty Liver	N/A
Recruiting	`NCT05370053` - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology	N/A
Recruiting	`NCT04371042` - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting	`NCT02265276` - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease	Phase 3
Completed	`NCT02347007` - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults	N/A
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms